News | September 21, 2009

CardiacAssist Partners with Mentice to Showcase Transseptal Puncture Training Simulation

September 21, 2009 — CardiacAssist Inc. announced today that it will showcase transseptal puncture training simulation, developed by Mentice Inc., at its TandemHeart® System exhibit in San Francisco at the “Transcatheter Therapeutics (TCT) 2009” Annual Scientific Session next week. TandemHeart is the only 5 lpm net flow, percutaneous "extracorporeal circulatory support" device approved by the FDA for sale in the U.S. The TandemHeart device can be placed rapidly in a cath lab or an operating room—providing effective, reliable, temporary circulatory support for critically ill patients. TandemHeart is fully reimbursed by Medicare under existing DRG codes.

While transseptal puncture of the interatrial septum was introduced nearly 50 years ago, it remains a difficult procedure. Renewed interest in transseptal left heart catheterization is on the rise due to the development of left side catheter ablation and the emergence of percutaneous technologies to treat mitral and aortic valve disease. Indeed, the transseptal puncture technique has now been used in more than 1,500 TandemHeart cases by more than 300 physicians.

“We believe it is imperative for cardiologists to be knowledgeable about the transseptal puncture technique, and the Mentice training simulation is designed to show them how to perform a simple and safe transseptal puncture,” said CardiacAssist CEO Michael Garippa. “We are pleased to be partnering with Mentice to offer cardiologists the best simulation-training possible, and we expect to train more than 1,000 physicians as soon as possible to be ‘Tandem-ready’.”

“TCT 2009” will be held at the Moscone Convention Center in San Francisco, Sept. 21-25, 2009. CardiacAssist will be in booth number 2005 with information and displays pertaining to the TandemHeart System. Additionally, CardiacAssist will host a symposium—“Clinical Innovations and TandemHeart™ Support”—by invitation only on Thursday, Sept. 24th, from 6-8 p.m. at Morton’s Steak House, 400 Post Street.

The Symposium will feature presentations of cases that have saved patients’ lives at leading medical institutions across the country; presenters will include: Dr. Steven Burstein, Good Samaritan Hospital, Los Angeles; Dr. Kirk Garrett, Lenox Hill Hospital, New York City; and Dr. Srijoy Mahapatra, University of Virginia Health System, Charlottesville, Va. Current and prospective customers who are interested in attending the Symposium should visit CardiacAssist’s booth to receive an invitation.

To RSVP for the event, please contact Monica Bush at 412-963-7770, extension 247 or via email at [email protected]

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init